Cargando…

Clinical phenotypes and outcomes in children with multisystem inflammatory syndrome across SARS-CoV-2 variant eras: a multinational study from the 4CE consortium

BACKGROUND: Multisystem inflammatory syndrome in children (MIS-C) is a severe complication of SARS-CoV-2 infection. It remains unclear how MIS-C phenotypes vary across SARS-CoV-2 variants. We aimed to investigate clinical characteristics and outcomes of MIS-C across SARS-CoV-2 eras. METHODS: We perf...

Descripción completa

Detalles Bibliográficos
Autores principales: Sperotto, Francesca, Gutiérrez-Sacristán, Alba, Makwana, Simran, Li, Xiudi, Rofeberg, Valerie N., Cai, Tianxi, Bourgeois, Florence T., Omenn, Gilbert S., Hanauer, David A., Sáez, Carlos, Bonzel, Clara-Lea, Bucholz, Emily, Dionne, Audrey, Elias, Matthew D., García-Barrio, Noelia, González, Tomás González, Issitt, Richard W., Kernan, Kate F., Laird-Gion, Jessica, Maidlow, Sarah E., Mandl, Kenneth D., Ahooyi, Taha Mohseni, Moraleda, Cinta, Morris, Michele, Moshal, Karyn L., Pedrera-Jiménez, Miguel, Shah, Mohsin A., South, Andrew M., Spiridou, Anastasia, Taylor, Deanne M., Verdy, Guillaume, Visweswaran, Shyam, Wang, Xuan, Xia, Zongqi, Zachariasse, Joany M., Newburger, Jane W., Avillach, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511777/
https://www.ncbi.nlm.nih.gov/pubmed/37745025
http://dx.doi.org/10.1016/j.eclinm.2023.102212
_version_ 1785108217048596480
author Sperotto, Francesca
Gutiérrez-Sacristán, Alba
Makwana, Simran
Li, Xiudi
Rofeberg, Valerie N.
Cai, Tianxi
Bourgeois, Florence T.
Omenn, Gilbert S.
Hanauer, David A.
Sáez, Carlos
Bonzel, Clara-Lea
Bucholz, Emily
Dionne, Audrey
Elias, Matthew D.
García-Barrio, Noelia
González, Tomás González
Issitt, Richard W.
Kernan, Kate F.
Laird-Gion, Jessica
Maidlow, Sarah E.
Mandl, Kenneth D.
Ahooyi, Taha Mohseni
Moraleda, Cinta
Morris, Michele
Moshal, Karyn L.
Pedrera-Jiménez, Miguel
Shah, Mohsin A.
South, Andrew M.
Spiridou, Anastasia
Taylor, Deanne M.
Verdy, Guillaume
Visweswaran, Shyam
Wang, Xuan
Xia, Zongqi
Zachariasse, Joany M.
Newburger, Jane W.
Avillach, Paul
author_facet Sperotto, Francesca
Gutiérrez-Sacristán, Alba
Makwana, Simran
Li, Xiudi
Rofeberg, Valerie N.
Cai, Tianxi
Bourgeois, Florence T.
Omenn, Gilbert S.
Hanauer, David A.
Sáez, Carlos
Bonzel, Clara-Lea
Bucholz, Emily
Dionne, Audrey
Elias, Matthew D.
García-Barrio, Noelia
González, Tomás González
Issitt, Richard W.
Kernan, Kate F.
Laird-Gion, Jessica
Maidlow, Sarah E.
Mandl, Kenneth D.
Ahooyi, Taha Mohseni
Moraleda, Cinta
Morris, Michele
Moshal, Karyn L.
Pedrera-Jiménez, Miguel
Shah, Mohsin A.
South, Andrew M.
Spiridou, Anastasia
Taylor, Deanne M.
Verdy, Guillaume
Visweswaran, Shyam
Wang, Xuan
Xia, Zongqi
Zachariasse, Joany M.
Newburger, Jane W.
Avillach, Paul
author_sort Sperotto, Francesca
collection PubMed
description BACKGROUND: Multisystem inflammatory syndrome in children (MIS-C) is a severe complication of SARS-CoV-2 infection. It remains unclear how MIS-C phenotypes vary across SARS-CoV-2 variants. We aimed to investigate clinical characteristics and outcomes of MIS-C across SARS-CoV-2 eras. METHODS: We performed a multicentre observational retrospective study including seven paediatric hospitals in four countries (France, Spain, U.K., and U.S.). All consecutive confirmed patients with MIS-C hospitalised between February 1st, 2020, and May 31st, 2022, were included. Electronic Health Records (EHR) data were used to calculate pooled risk differences (RD) and effect sizes (ES) at site level, using Alpha as reference. Meta-analysis was used to pool data across sites. FINDINGS: Of 598 patients with MIS-C (61% male, 39% female; mean age 9.7 years [SD 4.5]), 383 (64%) were admitted in the Alpha era, 111 (19%) in the Delta era, and 104 (17%) in the Omicron era. Compared with patients admitted in the Alpha era, those admitted in the Delta era were younger (ES −1.18 years [95% CI −2.05, −0.32]), had fewer respiratory symptoms (RD −0.15 [95% CI −0.33, −0.04]), less frequent non-cardiogenic shock or systemic inflammatory response syndrome (SIRS) (RD −0.35 [95% CI −0.64, −0.07]), lower lymphocyte count (ES −0.16 × 10(9)/uL [95% CI −0.30, −0.01]), lower C-reactive protein (ES −28.5 mg/L [95% CI −46.3, −10.7]), and lower troponin (ES −0.14 ng/mL [95% CI −0.26, −0.03]). Patients admitted in the Omicron versus Alpha eras were younger (ES −1.6 years [95% CI −2.5, −0.8]), had less frequent SIRS (RD −0.18 [95% CI −0.30, −0.05]), lower lymphocyte count (ES −0.39 × 10(9)/uL [95% CI −0.52, −0.25]), lower troponin (ES −0.16 ng/mL [95% CI −0.30, −0.01]) and less frequently received anticoagulation therapy (RD −0.19 [95% CI −0.37, −0.04]). Length of hospitalization was shorter in the Delta versus Alpha eras (−1.3 days [95% CI −2.3, −0.4]). INTERPRETATION: Our study suggested that MIS-C clinical phenotypes varied across SARS-CoV-2 eras, with patients in Delta and Omicron eras being younger and less sick. EHR data can be effectively leveraged to identify rare complications of pandemic diseases and their variation over time. FUNDING: None.
format Online
Article
Text
id pubmed-10511777
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-105117772023-09-22 Clinical phenotypes and outcomes in children with multisystem inflammatory syndrome across SARS-CoV-2 variant eras: a multinational study from the 4CE consortium Sperotto, Francesca Gutiérrez-Sacristán, Alba Makwana, Simran Li, Xiudi Rofeberg, Valerie N. Cai, Tianxi Bourgeois, Florence T. Omenn, Gilbert S. Hanauer, David A. Sáez, Carlos Bonzel, Clara-Lea Bucholz, Emily Dionne, Audrey Elias, Matthew D. García-Barrio, Noelia González, Tomás González Issitt, Richard W. Kernan, Kate F. Laird-Gion, Jessica Maidlow, Sarah E. Mandl, Kenneth D. Ahooyi, Taha Mohseni Moraleda, Cinta Morris, Michele Moshal, Karyn L. Pedrera-Jiménez, Miguel Shah, Mohsin A. South, Andrew M. Spiridou, Anastasia Taylor, Deanne M. Verdy, Guillaume Visweswaran, Shyam Wang, Xuan Xia, Zongqi Zachariasse, Joany M. Newburger, Jane W. Avillach, Paul eClinicalMedicine Articles BACKGROUND: Multisystem inflammatory syndrome in children (MIS-C) is a severe complication of SARS-CoV-2 infection. It remains unclear how MIS-C phenotypes vary across SARS-CoV-2 variants. We aimed to investigate clinical characteristics and outcomes of MIS-C across SARS-CoV-2 eras. METHODS: We performed a multicentre observational retrospective study including seven paediatric hospitals in four countries (France, Spain, U.K., and U.S.). All consecutive confirmed patients with MIS-C hospitalised between February 1st, 2020, and May 31st, 2022, were included. Electronic Health Records (EHR) data were used to calculate pooled risk differences (RD) and effect sizes (ES) at site level, using Alpha as reference. Meta-analysis was used to pool data across sites. FINDINGS: Of 598 patients with MIS-C (61% male, 39% female; mean age 9.7 years [SD 4.5]), 383 (64%) were admitted in the Alpha era, 111 (19%) in the Delta era, and 104 (17%) in the Omicron era. Compared with patients admitted in the Alpha era, those admitted in the Delta era were younger (ES −1.18 years [95% CI −2.05, −0.32]), had fewer respiratory symptoms (RD −0.15 [95% CI −0.33, −0.04]), less frequent non-cardiogenic shock or systemic inflammatory response syndrome (SIRS) (RD −0.35 [95% CI −0.64, −0.07]), lower lymphocyte count (ES −0.16 × 10(9)/uL [95% CI −0.30, −0.01]), lower C-reactive protein (ES −28.5 mg/L [95% CI −46.3, −10.7]), and lower troponin (ES −0.14 ng/mL [95% CI −0.26, −0.03]). Patients admitted in the Omicron versus Alpha eras were younger (ES −1.6 years [95% CI −2.5, −0.8]), had less frequent SIRS (RD −0.18 [95% CI −0.30, −0.05]), lower lymphocyte count (ES −0.39 × 10(9)/uL [95% CI −0.52, −0.25]), lower troponin (ES −0.16 ng/mL [95% CI −0.30, −0.01]) and less frequently received anticoagulation therapy (RD −0.19 [95% CI −0.37, −0.04]). Length of hospitalization was shorter in the Delta versus Alpha eras (−1.3 days [95% CI −2.3, −0.4]). INTERPRETATION: Our study suggested that MIS-C clinical phenotypes varied across SARS-CoV-2 eras, with patients in Delta and Omicron eras being younger and less sick. EHR data can be effectively leveraged to identify rare complications of pandemic diseases and their variation over time. FUNDING: None. Elsevier 2023-09-14 /pmc/articles/PMC10511777/ /pubmed/37745025 http://dx.doi.org/10.1016/j.eclinm.2023.102212 Text en © 2023 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Articles
Sperotto, Francesca
Gutiérrez-Sacristán, Alba
Makwana, Simran
Li, Xiudi
Rofeberg, Valerie N.
Cai, Tianxi
Bourgeois, Florence T.
Omenn, Gilbert S.
Hanauer, David A.
Sáez, Carlos
Bonzel, Clara-Lea
Bucholz, Emily
Dionne, Audrey
Elias, Matthew D.
García-Barrio, Noelia
González, Tomás González
Issitt, Richard W.
Kernan, Kate F.
Laird-Gion, Jessica
Maidlow, Sarah E.
Mandl, Kenneth D.
Ahooyi, Taha Mohseni
Moraleda, Cinta
Morris, Michele
Moshal, Karyn L.
Pedrera-Jiménez, Miguel
Shah, Mohsin A.
South, Andrew M.
Spiridou, Anastasia
Taylor, Deanne M.
Verdy, Guillaume
Visweswaran, Shyam
Wang, Xuan
Xia, Zongqi
Zachariasse, Joany M.
Newburger, Jane W.
Avillach, Paul
Clinical phenotypes and outcomes in children with multisystem inflammatory syndrome across SARS-CoV-2 variant eras: a multinational study from the 4CE consortium
title Clinical phenotypes and outcomes in children with multisystem inflammatory syndrome across SARS-CoV-2 variant eras: a multinational study from the 4CE consortium
title_full Clinical phenotypes and outcomes in children with multisystem inflammatory syndrome across SARS-CoV-2 variant eras: a multinational study from the 4CE consortium
title_fullStr Clinical phenotypes and outcomes in children with multisystem inflammatory syndrome across SARS-CoV-2 variant eras: a multinational study from the 4CE consortium
title_full_unstemmed Clinical phenotypes and outcomes in children with multisystem inflammatory syndrome across SARS-CoV-2 variant eras: a multinational study from the 4CE consortium
title_short Clinical phenotypes and outcomes in children with multisystem inflammatory syndrome across SARS-CoV-2 variant eras: a multinational study from the 4CE consortium
title_sort clinical phenotypes and outcomes in children with multisystem inflammatory syndrome across sars-cov-2 variant eras: a multinational study from the 4ce consortium
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511777/
https://www.ncbi.nlm.nih.gov/pubmed/37745025
http://dx.doi.org/10.1016/j.eclinm.2023.102212
work_keys_str_mv AT sperottofrancesca clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium
AT gutierrezsacristanalba clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium
AT makwanasimran clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium
AT lixiudi clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium
AT rofebergvalerien clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium
AT caitianxi clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium
AT bourgeoisflorencet clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium
AT omenngilberts clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium
AT hanauerdavida clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium
AT saezcarlos clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium
AT bonzelclaralea clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium
AT bucholzemily clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium
AT dionneaudrey clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium
AT eliasmatthewd clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium
AT garciabarrionoelia clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium
AT gonzaleztomasgonzalez clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium
AT issittrichardw clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium
AT kernankatef clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium
AT lairdgionjessica clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium
AT maidlowsarahe clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium
AT mandlkennethd clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium
AT ahooyitahamohseni clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium
AT moraledacinta clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium
AT morrismichele clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium
AT moshalkarynl clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium
AT pedrerajimenezmiguel clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium
AT shahmohsina clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium
AT southandrewm clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium
AT spiridouanastasia clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium
AT taylordeannem clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium
AT verdyguillaume clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium
AT visweswaranshyam clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium
AT wangxuan clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium
AT xiazongqi clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium
AT zachariassejoanym clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium
AT clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium
AT newburgerjanew clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium
AT avillachpaul clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium